Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Veracyte, Inc.

A Decade of SG&A Evolution: Viking Therapeutics vs. Veracyte

In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Veracyte, Inc. and Viking Therapeutics, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Veracyte's SG&A costs have surged by over 350% from 2014 to 2023, reflecting its aggressive expansion and market penetration strategies. In contrast, Viking Therapeutics, while experiencing a significant increase, has maintained a more conservative growth in SG&A, with a rise of approximately 2,870% over the same period. This disparity highlights Veracyte's robust market activities compared to Viking's more measured approach. As of 2023, Veracyte's SG&A expenses are nearly five times those of Viking, underscoring its larger operational scale. These insights provide a window into the strategic priorities of these biotech firms, offering investors a glimpse into their operational dynamics.